Drug Profile
Research programme: Huntington's disease therapeutics - Vertex Pharmaceuticals
Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Vertex Pharmaceuticals
- Class Small molecules
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Huntington's disease
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for research development in Huntington's-disease in USA
- 23 Mar 2011 This research programme appears to be ongoing in USA
- 19 Jun 2008 Early research in Huntington's disease in USA (unspecified route)